Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Ketamine for Chronic Cluster Headache
NCT04179266Phase 2Completed
- Sponsor
- CCH Pharma Pty Ltd.
- Start
- Nov 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ketamine in Cluster Headache (CH), sponsored by CCH Pharma Pty Ltd. Primary endpoint: Effect on pain intensity at 15 min (50% reduction). Started Nov 2019; status: completed.
02
Drugs
ketamine
03
Conditions
Cluster Headache (CH)
Beyond the preview
Go deeper on NCT04179266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04179266.